

Supplementary information for:

Highly stereoselective synthesis of indanes with four stereogenic centers via sequential Michael reaction and [3+2] cycloaddition

Pei Juan Chua, Bin Tan, Limin Yang, Xiaofei Zeng and Guofu Zhong*

Division of Chemistry & Biological Chemistry, School of Physical & Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371, Singapore

Table of Contents

1. General Information	S2
2. General Experimental Procedures for Preparation of Aldehydes 1	S3
3. Experimental data for the Preparation of Aldehydes 1	S4
4. General Experimental Procedures for the Synthesis of Indanes 4	S9
5. Experimental data of Compounds 4a-4k	S9
6. Experimental data of Compound A	S15
7. Experimental Procedure and Data for the Synthesis α -Hydroxy- γ -Amino Acid Derivative 5	S15
8. Experimental Procedure and Data for the Synthesis α -Hydroxy- γ -lactam Derivative 6	S16
9. Proposed Catalytic Cycle and Reaction Pathway of the Sequential Reaction	S17
10. ^1H and ^{13}C NMR Spectra of Compounds 7a-9d and 1a-e	S18
11. ^1H and ^{13}C NMR Spectra of Compounds 4a-4k	S32
12. ^1H and ^{13}C NMR Spectra of Compound A	S43
13. ^1H and ^{13}C NMR Spectra of Compounds 5	S44
14. ^1H and ^{13}C NMR Spectra of Compound 6	S45
15. HPLC Spectra of Compounds 4a-4k	S46
16. HPLC Spectra of Compound A	S57
17. HPLC Spectra of Compound 5	S58
18. HPLC Spectra of Compound 6	S59

General Information:

Analytical thin layer chromatography (TLC) was performed using Merck 60 F254 precoated silica gel plate (0.2 mm thickness). Subsequent to elution, plates were visualized using UV radiation (254 nm) on Spectroline Model ENF-24061/F 254 nm. Further visualization was possible by staining with basic solution of potassium permanganate or acidic solution of ceric molybdate. Flash chromatography was performed using Merck silica gel 60 with freshly distilled solvents. Columns were typically packed as slurry and equilibrated with the appropriate solvent system prior to use.

Proton nuclear magnetic resonance spectra (^1H NMR) were recorded on Bruker AMX 400 spectrophotometer (CDCl_3 as solvent). Chemical shifts for ^1H NMR spectra are reported as δ in units of parts per million (ppm) downfield from SiMe_4 (δ 0.0) and relative to the signal of SiMe_4 (δ 0.0, singlet). Multiplicities were given as: s (singlet), d (doublet), t (triplet), dd (doublets of doublet) or m (multiplets). The number of protons (n) for a given resonance is indicated by nH. Coupling constants are reported as a J value in Hz. Carbon nuclear magnetic resonance spectra (^{13}C NMR) are reported as δ in units of parts per million (ppm) downfield from SiMe_4 (δ 0.0) and relative to the signal of chloroform-d (δ 77.23, triplet).


Enantioselectivities were determined by High Performance Liquid Chromatography (HPLC) analysis employing a Daicel Chirapak AD-H (0.46cm x 25 cm), Chirapak AS-H (0.46cm x 25 cm), Chiracel OD-H (0.46cm x 25 cm) column.

Optical rotations were measured in CHCl_3 on a *Schmidt + Haensdch* polarimeter (Polartronic MH8) with a 1 cm cell (c given in g/100 mL).

High resolution mass spectrometry (HRMS) was recorded on Finnigan MAT 95 \times P spectrometer.

The enantiomers used to determine the ee values were synthesized with DL-proline as catalyst. All other reagents were available from commercial sources and used without further purification.

Typical procedures for the preparation of aldehydes 1:



(Adapted from K. Uchida, S. Yokoshima, T. Kan, T. Fukuyama. *Org. Lett.*, **2006**, *8*, 5311–5313)
2.0 M sodium bis(trimethylsilyl)amide in tetrahydrofuran (6 mL, 12 mmol, 1.2 equiv.) was added dropwise to a stirred solution of (methoxymethyl)triphenylphosphonium chloride (3.77 g, 11 mmol, 1.1 equiv.) in 20 mL of anhydrous tetrahydrofuran at 0 °C under nitrogen atmosphere for 2 hours. A solution of the corresponding bromobenzaldehyde **6** (10 mmol) was then added dropwise to the reaction mixture. After stirring at 0 °C for 10 minutes, the reaction mixture was allowed to warm to room temperature (22 °C) and stirred for another 2 hours. The yellow solution was quenched with saturated aqueous ammonium chloride (5 mL) and the solvent was evaporated under reduced pressure. Diethyl ether was added to the residue and the mixture was filtered. The filtrate was washed with sodium bicarbonate, water and then finally with brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (hexane:dichloromethane = 9:1) to give compound **7**. The product was the mixture of *E* and *Z* isomers.

(Adapted from M.-Y. Lin, A. Das, R.-S. Liu. *J. Am. Chem. Soc.*, **2006**, *128*, 9340–9341)
2.0 M *n*-butyllithium in cyclohexane (4 mL, 9.6 mmol, 1.2 equiv.) was added dropwise to a stirring solution compound **7** (8 mmol) in 20 mL anhydrous tetrahydrofuran at -78 °C under nitrogen atmosphere. After stirring at -78 °C for 2 hours, anhydrous N,N-dimethylformamide (0.92 mL, 12 mmol, 1.5 equiv.) was added to form a light yellow solution. After 30 min, 25 mL water was added to reaction mixture, extracted with diethyl ether and the combined organic layers were concentrated under reduce pressure. The crude product was eluted through a silica column (hexane:EtOAc = 19:1) to afford compound **8**. The product was the mixture of *E* and *Z* isomers.

(Adapted from B. Tan, D. Zhu, L. Zhang, P. J. Chua, X. Zeng, G. Zhong, *Chem. Eur. J.* **2010**, *16*, 3842-3845)


Corresponding ylide **10** (1.1 equiv) was added portion wise to a stirring solution of compound **8** (6 mmol) in 10 mL of dichloromethane at 23 °C and the reaction was stirred overnight. Diethyl ether was added to the residue and the mixture was filtered. The filtrate was washed with sodium bicarbonate, water and then finally with brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (hexane:dichloromethane = 9:1) to give compound **9**. The product was the mixture of *E* and *Z* isomers.

(Adapted from F. Richter, M. Bauer, C. Perez, C. Maichle-Mössmer, M. E. Maier. *J. Org. Chem.* **2002**, *67*, 2474-2480)

70% perchloric acid in water (7 mL) was added dropwise to a stirring solution of compound **8** (5 mmol) in diethyl ether 10 mL at 0 °C. After 10 minutes, the cooling bath was removed and stirring continued until the reaction proceeds to completion (reaction monitored by TLC). The mixture was diluted with water (10 mL) and extracted with ethyl acetate. The combined organic layers were washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and concentrated *in vacuo* to afford compound **1**.

Experimental data of Compounds **7a-9d** and **1a-e**.

1-bromo-2-(2-methoxyvinyl)benzene (**7a**)




Compound **7a** was prepared according to the general procedure from 2-bromobenzaldehyde **6a** (1.85 g, 10 mmol) to provide the title compound as a pale yellow liquid (1.97 g, 92% yield) after flash column chromatography. The product was the mixture of *E* and *Z* isomers (ratio 1:1.6)

¹H NMR (400 MHz, CDCl₃): δ 8.03 (1H, d, *J* = 8 Hz), 7.53 (2.6H, d, *J* = 8 Hz), 7.34 (1.6H, d, *J* = 8 Hz), 7.26-7.18 (2.6H, m), 7.02-6.96 (4.2H, m), 6.25 (1H, d, *J* = 7.2 Hz), 6.09 (1.6H, d, *J* = 12.8 Hz), 5.60 (1H, d, *J* = 7.2 Hz), 3.78, 3.73 (7.8H, s).

¹³C NMR (100 MHz, CDCl₃): 150.7, 149.4, 136.5, 135.3, 133.1, 132.7, 130.5, 127.7, 127.3, 127.3, 127.3, 125.9, 123.2, 122.9, 104.6, 104.0, 61.1, 56.8.

2-(2-methoxyvinyl)benzaldehyde (**8a**) (new compound)




Compound **8a** was prepared according to the general procedure from 1-bromo-2-(2-methoxyvinyl)benzene (**7a**) (1.70 g, 8 mmol) to provide the title compound as a pale yellow liquid (1.26g, 97% yield) after flash column chromatography. The product was the mixture of *E* and *Z* isomers (ratio 1:1).

^1H NMR (400 MHz, CDCl_3): δ 10.21 (2H, d, $J = 15.6$ Hz), 7.88 (1H, d, $J = 7.6$ Hz), 7.79 (2H, t, $J = 7.6$ Hz), 7.53-7.47 (2H, m), 7.42 (1H, d, $J = 7.6$ Hz), 7.34-7.29 (2H, m), 7.02 (1H, d, $J = 12.8$ Hz), 6.75 (1H, d, $J = 12.8$ Hz), 6.32 (1H, d, $J = 7.2$ Hz), 6.11 (1H, d, $J = 7.2$ Hz), 3.77, 3.76 (6H, s).

^{13}C NMR (100 MHz, CDCl_3): 192.8, 152.3, 150.2, 138.9, 137.6, 133.7, 133.3, 132.5, 132.1, 131.9, 131.2, 130.2, 126.3, 126.1, 126.0, 101.2, 100.6, 60.7, 56.7.

HRMS (ESI) calcd for $\text{C}_{10}\text{H}_{11}\text{O}_2$, m/z 163.0759 $[\text{M}+\text{H}]$, found 163.0751.

((*E*)-ethyl 3-(2-(2-methoxyvinyl)phenyl)acrylate (**9a**) (new compound)




Compound **9a** was prepared according to the general procedure from 2-(2-methoxyvinyl)benzaldehyde (**8a**) (0.97 g, 6 mmol) and ylide **10a** (2.30g, 1.1 equiv.) to provide the title compound as a pale yellow liquid (1.27g, 91% yield) after flash column chromatography. The product was the mixture of *E* and *Z* isomers (ratio 1:1).

^1H NMR (400 MHz, CDCl_3): δ 8.01 (2H, dd, $J = 15.8, 5.2$ Hz), 7.83 (1H, d, $J = 7.9$ Hz), 7.50 (2H, d, $J = 7.8$ Hz), 7.32-7.26 (3H, m), 7.23-7.13 (2H, m), 6.82 (1H, d, $J = 10.6$ Hz), 6.33 (2H, dd, $J = 15.9, 8.3$ Hz), 6.22 (1H, d, $J = 7.1$ Hz), 6.04 (1H, d, $J = 12.7$ Hz), 5.46 (1H, d, $J = 7.1$ Hz), 4.26 (4H, dq, $J = 7.2, 2.3$ Hz), 3.71, 3.70 (6H, s), 1.33 (6H, t, $J = 7.2$ Hz).

^{13}C NMR (100 MHz, CDCl_3): 167.2, 167.1, 151.2, 149.0, 143.1, 142.8, 136.5, 135.2, 132.0, 132.0, 130.1, 130.0, 129.7, 127.1, 126.8, 126.7, 126.4, 119.5, 119.4, 102.2, 101.9, 60.7, 60.5, 60.5, 56.8, 14.4.

HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{17}\text{O}_3$, m/z 233.1178 $[\text{M}+\text{H}]$, found 233.1181.

(*E*)-ethyl 3-(2-(formylmethyl)phenyl)acrylate (**1a**) (new compound)




Compound **1a** was prepared according to the general procedure from ((*E*)-ethyl 3-(2-(2-methoxyvinyl)phenyl)acrylate **9a** (1.16 g, 5 mmol) to provide the title compound as a pale yellow liquid (1.06g, 98% yield) after concentration *in vacuo*.

^1H NMR (400 MHz, CDCl_3): δ 9.75 (1H, s), 7.83 (1H, d, $J = 15.7$ Hz), 7.64 (1H, d, $J = 7.5$ Hz), 7.41-7.33 (2H, m), 7.22 (1H, d, $J = 7.3$ Hz), 6.39 (1H, d, $J = 15.7$ Hz), 4.27 (2H, q, $J = 7.1$ Hz), 3.89 (2H, s), 1.34 (3H, t, $J = 7.1$ Hz).

^{13}C NMR (100 MHz, CDCl_3): 198.3, 166.6, 141.1, 134.3, 131.7, 131.4, 130.4, 128.2, 127.1, 121.0, 60.7, 48.1, 14.3.

HRMS (ESI) calcd for $\text{C}_{12}\text{H}_{13}\text{O}_3$, m/z 205.0865 $[\text{M}+\text{H}]$, found 205.0866.

1-bromo-4-methoxy-2-(2-methoxyvinyl)benzene (**7b**)




Compound **7b** was prepared according to the general procedure from 2-bromo-5-methoxybenzaldehyde **6b** (2.31 g, 10 mmol) to provide the title compound as a pale yellow liquid (1.87 g, 77% yield) after flash column chromatography. The product was the

mixture of *E* and *Z* isomers (ratio 1:1.3)

^1H NMR (400 MHz, CDCl_3): δ 7.65 (1H, d, $J = 2.6$ Hz), 7.38 (2.3H, d, $J = 8.8$ Hz), 6.96 (1.3H, d, $J = 12.9$ Hz), 6.85 (1.3H, d, $J = 2.2$ Hz), 6.57-6.56 (1.3H, m), 6.21 (1H, d, $J = 7.2$ Hz), 6.03 (1.3H, d, $J = 12.8$ Hz), 5.55 (1H, d, $J = 7.2$ Hz), 3.75-3.69 (13.8H, m).

^{13}C NMR (100 MHz, CDCl_3): 159.1, 158.7, 150.7, 149.6, 137.1, 135.8, 133.5, 132.9, 115.7, 113.8, 113.6, 113.2, 113.2, 111.1, 104.6, 103.9, 61.1, 56.7, 55.5, 55.5.

4-methoxy-2-(2-methoxyvinyl)benzaldehyde (**8b**) (new compound)




Compound **8b** was prepared according to the general procedure from 1-bromo-4-methoxy-2-(2-methoxyvinyl)benzene **7b** (1.70 g, 7 mmol) to provide the title compound as a pale yellow liquid (1.12 g, 77% yield) after flash column chromatography. The product was the mixture of *E* and *Z* isomers (ratio 1:1.5).

^1H NMR (400 MHz, CDCl_3): δ 10.06 (2.5H, d, $J = 10.2$ Hz), 7.73-7.70 (2.5H, m), 7.48 (1H, d, $J = 2.4$ Hz), 7.03 (1.5H, d, $J = 12.8$ Hz), 6.86-6.75 (5.5H, m), 6.31 (1H, d, $J = 7.4$ Hz), 6.22 (1H, d, $J = 7.1$ Hz), 3.86 (7.5H, s), 3.76 (7.5H, d, $J = 11.9$ Hz).

^{13}C NMR (100 MHz, CDCl_3): 191.5, 191.4, 163.8, 163.6, 152.3, 150.7, 141.4, 139.7, 135.4, 134.5, 126.1, 126.1, 115.2, 120.0, 111.9, 111.0, 101.4, 100.5, 61.0, 56.7, 55.5, 55.5.

HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{13}\text{O}_2$, m/z 193.0865 [$\text{M}+\text{H}$], found 193.0867.

(*2E*)-ethyl 3-(4-methoxy-2-(2-methoxyvinyl)phenyl)acrylate (**9b**) (new compound)



Compound **9b** was prepared according to the general procedure from 4-methoxy-2-(2-methoxyvinyl)benzaldehyde **8b** (1.04 g, 5 mmol) and ylide **10a** (1.91 g, 1.1 equiv.) to provide the title compound as a pale yellow liquid (0.76 g, 58% yield) after flash column chromatography. The product was the mixture of *E* and *Z*


isomers (ratio 1:1.6).

^1H NMR (400 MHz, CDCl_3): δ 7.96 (2.6H, dd, $J = 15.8, 9.2$ Hz), 7.50 (2.6H, d, $J = 15.7$ Hz), 7.46-7.40 (1.6H, m), 6.85-6.77 (2H, m), 6.71 (2.6H, d, $J = 8.6$ Hz), 6.26 (1.6H, d, $J = 5.6$ Hz), 6.22 (2.6H, d, $J = 6.5$ Hz), 6.04 (1H, d, $J = 12.6$ Hz), 5.47 (1.6H, d, $J = 7.2$ Hz), 4.24 (4H, q, $J = 7.0$ Hz), 3.78 (7.8H, s), 3.70 (7.8H, d, $J = 7.2$ Hz), 1.31 (7.8H, t, $J = 7.1$ Hz).

^{13}C NMR (100 MHz, CDCl_3): 167.4, 167.3, 161.0, 160.7, 151.2, 148.6, 142.8, 142.1, 138.3, 136.8, 128.4, 124.7, 119.7, 112.5, 111.3, 110.9, 102.3, 102.1, 60.7, 60.2, 60.2, 60.0, 56.7, 55.2, 55.1, 14.0.

HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{19}\text{O}_4$, m/z 263.1283 [$\text{M}+\text{H}$], found 263.1286.


(*E*)-ethyl 3-(2-(formylmethyl)-4-methoxyphenyl)acrylate (**1b**) (new compound)



Compound **1b** was prepared according to the general procedure from ((*2E*)-ethyl 3-(4-methoxy-2-(2-methoxyvinyl)phenyl)acrylate **9b** (0.73 g, 2.8 mmol) to provide the title compound as a pale

yellow liquid (0.43 g, 62% yield) after flash column chromatography (hexane:EtOAc = 9:1)
 ^1H NMR (400 MHz, CDCl_3): δ 9.71 (1H, s), 7.76 (1H, d, $J = 15.7$ Hz), 7.60 (1H, d, $J = 8.8$ Hz), 6.86 (1H, dd, $J = 8.7, 2.5$ Hz), 6.72 (1H, d, $J = 2.5$ Hz), 6.28 (1H, d, $J = 15.7$ Hz), 4.24 (2H, q, $J = 7.2$ Hz), 3.85 (2H, s), 3.81, (3H, s), 1.32 (3H, t, $J = 7.1$ Hz).
 ^{13}C NMR (100 MHz, CDCl_3): 198.1, 166.9, 161.2, 140.5, 133.6, 128.6, 126.6, 118.3, 116.5, 113.9, 60.4, 55.4, 48.1, 14.3.
HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{17}\text{O}_4$, m/z 249.1127 $[\text{M}+\text{H}]$, found 249.1132.


5-bromo-6-(2-methoxyvinyl)benzo[*d*][1,3]dioxole (**7c**)



Compound **7c** was prepared according to the general procedure from 6-bromobenzo[*d*][1,3]dioxole-5-carbaldehyde **6c** (2.29 g, 10 mmol) to provide the title compound as a pale yellow liquid (2.21 g, 86% yield) after flash column chromatography. The product was the mixture of *E* and *Z* isomers (ratio 1:3)

^1H NMR (400 MHz, CDCl_3): δ 7.61 (1H, s), 7.00, 6.99 (4H, s), 6.86 (3H, d, $J = 12.8$ Hz), 6.82 (3H, s), 6.15 (1H, d, $J = 7.2$ Hz), 6.02 (3H, d, $J = 12.9$ Hz), 5.94 (8H, s), 5.51 (1H, d, $J = 7.2$ Hz), 3.76, 3.70 (12H, s).
 ^{13}C NMR (100 MHz, CDCl_3): 149.3, 147.8, 147.3, 146.7, 146.3, 145.9, 129.2, 128.4, 113.0, 112.9, 112.3, 112.0, 109.4, 104.8, 104.3, 103.6, 101.5, 101.4, 60.4, 56.2.


6-(2-methoxyvinyl)benzo[*d*][1,3]dioxole-5-carbaldehyde (**8c**) (new compound)



Compound **8b** was prepared according to the general procedure from 5-bromo-6-(2-methoxyvinyl)benzo[*d*][1,3]dioxole **7c** (2.05 g, 8 mmol) and 1.7 M *tert*-butyllithium in tetrahydrofuran (5.7 mL, 9.6 mmol, 1.2 equiv.) to provide the title compound as a pale yellow liquid (1.44 g, 87% yield) after concentration *in vacuo*. The crude product was used directly for the next step without purification.

HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{11}\text{O}_4$, m/z 207.0657 $[\text{M}+\text{H}]$, found 207.0652.

(*E*)-ethyl 3-(6-(2-methoxyvinyl)benzo[*d*][1,3]dioxol-5-yl)acrylate (**9c**) (new compound)



Compound **9c** was prepared according to the general procedure from 6-(2-methoxyvinyl)benzo[*d*][1,3]dioxole-5-carbaldehyde **8c** (1.24 g, 6 mmol) and ylide **10a** (2.30 g, 1.1 equiv.) to provide the title compound as a pale yellow liquid (0.66 g, 40% yield) after flash column chromatography. The product was the mixture of *E*


and *Z* isomers (ratio 1:1.6).

^1H NMR (400 MHz, CDCl_3): δ 7.95 (2.6H, dd, $J = 15.7, 8.0$ Hz), 7.38, (1H, s), 7.01, (2.6H, s), 6.75 (1.6H, s), 6.72 (1H, s), 6.22-6.17 (3.2H, m), 6.03 (1.6H, d, $J = 12.7$ Hz), 5.97 (5.2H, s), 5.94 (1H, s), 5.45 (1H, d, $J = 7.2$ Hz), 4.25 (5.2H, q, $J = 7.1$ Hz), 3.75, 3.72 (7.8H, s), 1.33 (7.8H, t, $J = 7.1$ Hz).

^{13}C NMR (100 MHz, CDCl_3): 167.5, 167.5, 150.8, 149.8, 149.3, 148.4, 146.8, 146.5, 142.4, 142.2, 132.3, 131.0, 126.0, 125.7, 117.2, 117.1, 109.7, 106.7, 106.0, 105.8, 102.2, 101.8, 101.6, 101.5, 60.8, 60.6, 60.5, 57.0, 14.5.

HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{17}\text{O}_5$, m/z 277.1076 $[\text{M}+\text{H}]$, found 277.1078.

(*E*)-ethyl 3-(6-(2-oxoethyl)benzo[*d*][1,3]dioxol-5-yl)acrylate (**1c**) (new compound)




Compound **1c** was prepared according to the general procedure from (*E*)-ethyl 3-(6-(2-methoxyvinyl)benzo[*d*][1,3]dioxol-5-yl)acrylate **9c** (0.55 g, 2 mmol) to provide the title compound as a pale yellow liquid (0.47 g, 90% yield) after flash column chromatography (hexane:EtOAc = 9:1)

^1H NMR (400 MHz, CDCl_3): δ 10.3 (1H, s), 8.42 (1H, d, $J = 15.7$ Hz), 7.35 (1H, s), 7.06 (1H, s), 6.31 (1H, d, $J = 15.7$ Hz), 6.11 (1H, s), 4.29 (2H, q, $J = 7.2$ Hz), 1.35 (3H, t, $J = 7.1$ Hz).

^{13}C NMR (100 MHz, CDCl_3): 188.9, 166.4, 152.8, 149.8, 139.5, 134.1, 129.8, 122.6, 109.1, 107.0, 102.7, 61.0, 29.9, 14.5.

HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{15}\text{O}_5$, m/z 263.0919 $[\text{M}+\text{H}]$, found 263.0921.

((*E*)-methyl 3-(2-(2-methoxyvinyl)phenyl)acrylate (**9d**) (new compound)




Compound **9d** was prepared according to the general procedure from 2-(2-methoxyvinyl)benzaldehyde (**8a**) (0.97 g, 6 mmol) and ylide **10b** (2.20g, 1.1 equiv.) to provide the title compound as a pale yellow liquid (1.18g, 90% yield) after flash column chromatography. The product was the mixture of *E* and *Z* isomers (ratio 1:1.5).

^1H NMR (400 MHz, CDCl_3): δ 8.01 (2.5H, dd, $J = 15.9, 4.8$ Hz), 7.52 (1H, d, $J = 7.8$ Hz), 7.33 (2.5H, d, $J = 7.7$ Hz), 7.30 (4H, d, $J = 4.2$ Hz), 7.22-7.18 (2.5H, m), 6.83 (1.5H, d, $J = 12.7$ Hz), 6.34 (2.5H, dd, $J = 15.9, 9.4$ Hz), 6.25 (1H, d, $J = 7.1$ Hz), 6.04 (1.5H, d, $J = 12.7$ Hz), 5.47 (1H, d, $J = 7.1$ Hz), 3.81, 3.74 (15H, m).

^{13}C NMR (100 MHz, CDCl_3): 167.5, 167.4, 151.2, 149.0, 143.3, 143.0, 136.5, 135.3, 131.9, 131.9, 130.1, 129.9, 129.7, 127.1, 126.7, 126.7, 126.3, 119.0, 118.9, 102.1, 101.8, 60.6, 56.8, 51.7, 51.6.

HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{15}\text{O}_3$, m/z 219.1021 $[\text{M}+\text{H}]$, found 219.1017.

(*E*)-methyl 3-(2-(formylmethyl)phenyl)acrylate (**1d**) (new compound)




Compound **1d** was prepared according to the general procedure from ((*E*)-methyl 3-(2-(2-methoxyvinyl)phenyl)acrylate **9d** (1.10 g, 5 mmol) to provide the title compound as a pale yellow liquid (0.91g, 95% yield) after concentration *in vacuo*.

^1H NMR (400 MHz, CDCl_3): δ 9.74 (1H, s), 7.83 (1H, d, $J = 15.7$ Hz), 7.63 (1H, d, $J = 7.4$ Hz), 7.41-7.33 (2H, m), 7.22 (1H, d, $J = 7.3$ Hz), 6.39 (1H, d, $J = 15.7$ Hz), 3.88 (2H, s), 3.81 (3H, s).

^{13}C NMR (100 MHz, CDCl_3): 198.4, 167.2, 141.5, 134.4, 131.8, 131.5, 130.6, 128.4, 127.3, 120.8, 52.0, 48.3.

HRMS (ESI) calcd for $\text{C}_{12}\text{H}_{13}\text{O}_3$, m/z 205.0865 $[\text{M}+\text{H}]$, found 205.0868.

(E)-methyl 6-formylhex-2-enoate (**1e**)



Compound **1e** was prepared according to the procedure¹ from 5,5-dimethoxy-pentanal (1.46 g, 10 mmol) to provide the title compound as a pale yellow liquid (1.29 g, 83% yield).

^1H NMR (400 MHz, CDCl_3): δ 9.78 (1H, s), 6.97-6.89 (1H, m), 5.85 (1H, d, $J = 15.6$ Hz), 3.73 (3H, s), 2.49 (2H, t, $J = 7.2$ Hz), 2.29-2.23 (2H, m), 1.85-1.78 (2H, m).


^{13}C NMR (100 MHz, CDCl_3): 201.8, 167.1, 148.1, 122.1, 51.7, 43.2, 31.5, 20.5.

General experimental procedure for the synthesis of indanes with 3 stereogenic centers via tandem Michael-[3+2] cycloaddition reaction:

Corresponding aldehydes **1** (0.15 mmol, 1.5 equiv.) was added to a 5 mL drum vial containing a stirring mixture of 2-[diphenyl[(trimethylsilyloxy)methyl]-(2S)-pyrrolidine **I** (1.6 mg, 0.005 mmol, 20 mol %), 1,1-bis(phenylsulfonyl)ethylene **2** (30.8 mg, 0.1 mmol) and toluene (0.6 ml, 0.17 M) at -20 °C. The reaction was stirred at this temperature for 24 hours (reaction monitored by TLC). Respective hydroxyamines **3** (0.15 mmol, 1.5 equiv.) was then added to the reaction mixture and stirred at room temperature for 3 hours, unless otherwise stated. The reaction mixture was purified by flash column chromatography (Hexane:EtOAc = 85:15) yielding pure indanes **4**.

Experimental data of Compounds 4a-4k

(3*S*,3*aS*,8*S*,8*aR*)-ethyl 8-(2,2-bis(phenylsulfonyl)ethyl)-1-phenyl-3,3*a*,8,8*a*-tetrahydro-1*H*-indeno[2,1-*c*]isoxazole-3-carboxylate (**4a**) (new compound)



Indane **4a** was prepared according to the general procedure from (*E*)-ethyl 3-(2-(formylmethyl)phenyl)acrylate **1a** (35.4 mg, 0.15 mmol, 1.5 equiv.) and *N*-phenylhydroxyamine **3a** (16.3 mg, 0.15 mmol, 1.5 equiv.) to provide the title compound as a white solid (60.5 mg, 98% yield) after flash column chromatography on silica gel.

^1H NMR (400 MHz, CDCl_3): δ 7.79-7.11 (19H, m), 4.79-4.77 (1H, m), 4.51-4.48 (3H, m), 4.19-4.11 (2H, m), 4.68-3.66 (1H, m), 2.73-2.66 (1H, m), 2.57-2.50 (1H, m), 1.25 (3H, t, $J = 7.1$ Hz).

^{13}C NMR (100 MHz, CDCl_3): 170.3, 149.2, 142.9, 141.5, 138.3, 137.2, 134.9, 134.6, 130.1, 129.3, 129.3, 129.1, 128.7, 128.6, 125.1, 124.6, 124.4, 118.3, 83.4, 80.0, 76.5, 61.9, 56.0, 47.0, 31.1, 29.8, 14.2.


¹ Kumpulainen, E. T. T.; Koskinen, A. M. P.; Rissanen, K. *Org. Lett.*, **2007**, *9*, 5043.

HPLC: Chiralpak AD-H (hexane/*i*-PrOH, 50/50, flow rate 1 mL/min, λ = 220 nm),
 t_R (major) = 13.0 min, t_R (minor) = 39.8 min; 98% ee.

$[\alpha]_D^{22} = -74.7$ ($c = 1.5$, CHCl₃).

HRMS (ESI) calcd for C₃₃H₃₂NO₇S₂, m/z 618.1620 [M+H], found 618.1612.

(3*S*,3*aS*,8*S*,8*aR*)-ethyl 8-(2,2-bis(phenylsulfonyl)ethyl)-1-(4-bromophenyl)-3,3*a*,8,8*a*-tetrahydro-1*H*-indeno[2,1-*c*]isoxazole-3-carboxylate (**4b**) (new compound)



Indane **4b** was prepared according to the general procedure from (*E*)-ethyl 3-(2-(formylmethyl)phenyl)acrylate **1a** (35.4 mg, 0.15 mmol, 1.5 equiv.) and *N*-(4-bromophenyl)hydroxylamine **3b** (28.2 mg, 0.15 mmol, 1.5 equiv.) to provide the title compound as a white solid (64.1 mg, 92% yield) after flash column chromatography on silica gel.

¹H NMR (400 MHz, CDCl₃): δ 7.82-7.21 (18H, m), 4.78-4.75 (1H, m), 4.51-4.43 (3H, m), 4.24-4.14 (2H, m), 3.74-3.70 (1H, m), 2.72-2.65 (1H, m), 2.58-2.51 (1H, m), 1.27 (3H, t, $J = 7.1$ Hz).

¹³C NMR (100 MHz, CDCl₃): 170.2, 148.6, 142.7, 141.2, 138.2, 137.1, 135.0, 134.6, 132.1, 130.1, 129.4, 129.3, 129.0, 128.7, 125.1, 124.7, 119.4, 116.8, 83.4, 80.2, 68.2, 62.0, 56.0, 47.0, 29.7, 25.8, 14.3.


HPLC: Chiralpak AS-H (hexane/*i*-PrOH, 90/10, flow rate 1 mL/min, λ = 220 nm),

t_R (minor) = 81.3 min, t_R (major) = 114.0 min; 96% ee.

$[\alpha]_D^{22} = -88.7$ ($c = 1.5$, CHCl₃).

HRMS (ESI) calcd for C₃₃H₃₁NO₇S₂Br, m/z 696.0725 [M+H], found 696.0716.

(3*S*,3*aS*,8*S*,8*aR*)-ethyl 8-(2,2-bis(phenylsulfonyl)ethyl)-1-(3-chlorophenyl)-3,3*a*,8,8*a*-tetrahydro-1*H*-indeno[2,1-*c*]isoxazole-3-carboxylate (**4c**) (new compound)



Indane **4c** was prepared according to the general procedure from (*E*)-ethyl 3-(2-(formylmethyl)phenyl)acrylate **1a** (35.4 mg, 0.15 mmol, 1.5 equiv.) and *N*-(3-chlorophenyl)hydroxylamine **3c** (21.5 mg, 0.15 mmol, 1.5 equiv.) to provide the title compound as a white solid (63.2 mg, 97% yield) after flash column chromatography on silica gel.

¹H NMR (400 MHz, CDCl₃): δ 7.87-7.28 (13H, m), 7.24-7.03 (5H, m), 4.81 (1H, dd, $J = 7.1, 3.2$ Hz), 4.56-4.46 (3H, m), 4.21-4.12 (2H, m), 3.70-3.66 (1H, m), 2.71-2.66 (1H, m), 2.62-2.59 (1H, m), 1.28 (3H, t, $J = 7.2$ Hz).

¹³C NMR (100 MHz, CDCl₃): 170.2, 150.8, 142.6, 141.0, 138.2, 137.1, 135.1, 135.1, 135.0, 134.6, 130.3, 130.1, 129.4, 129.3, 129.0, 128.7, 125.0, 124.6, 123.5, 117.2, 114.6, 83.6, 80.2, 76.4, 62.1, 60.6, 55.6, 47.2, 29.8, 14.2.


HPLC: Chiralpak OD-H (hexane/*i*-PrOH, 90/10, flow rate 1 mL/min, λ = 220 nm),

t_R (major) = 40.4 min, t_R (minor) = 47.2 min; 98% ee.

$[\alpha]_D^{22} = -102.8$ ($c = 1.5$, CHCl_3).

HRMS (ESI) calcd for $\text{C}_{33}\text{H}_{31}\text{NO}_7\text{S}_2\text{Cl}$, m/z 652.1230 $[\text{M}+\text{H}]$, found 652.1234.

(3*S*,3*aS*,8*S*,8*aR*)-ethyl 8-(2,2-bis(phenylsulfonyl)ethyl)-1-(4-chlorophenyl)-3,3*a*,8,8*a*-tetrahydro-1*H*-indeno[2,1-*c*]isoxazole-3-carboxylate (**4d**) (new compound)



Indane **4d** was prepared according to the general procedure from (*E*)-ethyl 3-(2-(formylmethyl)phenyl)acrylate **1a** (35.4 mg, 0.15 mmol, 1.5 equiv.) and *N*-(4-chlorophenyl)hydroxylamine **3d** (21.5 mg, 0.15 mmol, 1.5 equiv.) to provide the title compound as a white solid (60.1 mg, 92% yield) after flash column chromatography on silica gel.

^1H NMR (400 MHz, CDCl_3): δ 7.81-7.21 (18H, m), 4.75 (1H, dd, $J = 7.1, 2.9$ Hz), 4.51-4.43 (3H, m), 4.22-4.11 (2H, m), 3.73-3.70

(1H, m), 2.72-2.65 (1H, m), 2.57-2.50 (1H, m), 1.28 (3H, t, $J = 7.2$ Hz).

^{13}C NMR (100 MHz, CDCl_3): 170.2, 148.0, 142.7, 141.2, 138.2, 137.1, 135.0, 134.6, 130.1, 129.4, 129.3, 129.2, 129.0, 128.7, 125.1, 124.7, 119.3, 83.4, 80.2, 62.0, 60.6, 56.0, 47.0, 29.8, 21.2, 14.4, 14.3.


HPLC: Chiralpak AS-H (hexane/*i*-PrOH, 80/20, flow rate 1 mL/min, $\lambda = 220$ nm),

t_R (minor) = 29.6 min, t_R (major) = 39.5 min; 98% ee.

$[\alpha]_D^{22} = -96.3$ ($c = 1.3$, CHCl_3).

HRMS (ESI) calcd for $\text{C}_{33}\text{H}_{31}\text{NO}_7\text{S}_2\text{Cl}$, m/z 652.1230 $[\text{M}+\text{H}]$, found 652.1237.

(3*S*,3*aS*,8*S*,8*aR*)-ethyl 8-(2,2-bis(phenylsulfonyl)ethyl)-1-*o*-tolyl-3,3*a*,8,8*a*-tetrahydro-1*H*-indeno[2,1-*c*]isoxazole-3-carboxylate (**4e**) (new compound)



Indane **4e** was prepared according to the general procedure from (*E*)-ethyl 3-(2-(formylmethyl)phenyl)acrylate **1a** (35.4 mg, 0.15 mmol, 1.5 equiv.) and *N*-*o*-tolylhydroxylamine **3e** (18.5 mg, 0.15 mmol, 1.5 equiv.) to provide the title compound as a white solid (61.0 mg, 97% yield) after flash column chromatography on silica gel.

^1H NMR (400 MHz, CDCl_3): δ 7.67-7.29 (15H, m), 7.25-7.21 (3H, m), 4.62 (1H, dd, $J = 7.4, 4.6$ Hz), 4.50 (1H, dd, $J = 7.2, 2.3$ Hz),

4.40 (1H, d, $J = 4.6$ Hz), 4.34 (1H, dd, $J = 7.4, 3.4$ Hz), 4.13-4.09 (1H, m), 4.01-3.97 (1H, m), 3.39-3.36 (1H, m), 2.69-2.62 (1H, m), 2.39 (3H, s), 2.38-2.31 (1H, m), 1.17 (3H, t, $J = 7.1$ Hz).

^{13}C NMR (100 MHz, CDCl_3): 170.6, 145.1, 143.3, 142.3, 138.3, 137.3, 136.9, 134.8, 134.6, 131.3, 129.8, 129.4, 129.2, 128.6, 128.5, 127.5, 126.8, 125.2, 124.6, 121.5, 83.1, 80.0, 74.5, 61.6, 57.6, 46.9, 30.0, 18.6, 14.2.


HPLC: Chiralpak AD-H (hexane/*i*-PrOH, 50/50, flow rate 1 mL/min, $\lambda = 220$ nm),

t_R (major) = 8.6 min, t_R (minor) = 46.9 min; 95% ee.

$[\alpha]_D^{22} = -57.8$ ($c = 0.9$, CHCl_3).

HRMS (ESI) calcd for $C_{34}H_{34}NO_7S_2$, m/z 632.1777 [M+H], found 632.1764.

(3*S*,3*aS*,8*S*,8*aR*)-ethyl 8-(2,2-bis(phenylsulfonyl)ethyl)-1-*p*-tolyl-3,3*a*,8,8*a*-tetrahydro-1*H*-indeno[2,1-*c*]isoxazole-3-carboxylate (**4f**) (new compound)



Indane **4f** was prepared according to the general procedure from (*E*)-ethyl 3-(2-(formylmethyl)phenyl)acrylate **1a** (35.4 mg, 0.15 mmol, 1.5 equiv.) and *N*-*p*-tolylhydroxylamine **3f** (18.5 mg, 0.15 mmol, 1.5 equiv.) to provide the title compound as a white solid (60.8 mg, 96% yield) after flash column chromatography on silica gel.

1H NMR (400 MHz, $CDCl_3$): δ 7.76-7.16 (18H, m), 4.15-4.68 (1H, m), 4.47-4.43 (2H, m), 4.37-4.35 (1H, m), 4.22-4.14 (2H, m), 3.66-3.61 (1H, m), 2.72-2.65 (1H, m), 2.51-2.43 (1H, m), 2.35 (1H, s), 1.27 (3H, t, $J = 7.1$ Hz).

^{13}C NMR (100 MHz, $CDCl_3$): 170.4, 146.5, 143.0, 141.7, 138.3, 137.2, 134.8, 134.7, 134.6, 130.1, 129.8, 129.3, 129.3, 129.2, 128.6, 128.6, 125.1, 124.7, 119.4, 83.2, 80.0, 76.9, 61.8, 56.3, 46.9, 29.8, 21.1, 14.3.


HPLC: Chiralpak AS-H (hexane/*i*-PrOH, 80/20, flow rate 1 mL/min, $\lambda = 220$ nm),

t_R (minor) = 41.9 min, t_R (major) = 64.9 min; 98% ee.

$[\alpha]_D^{22} = -73.5$ ($c = 1.5$, $CHCl_3$).

HRMS (ESI) calcd for $C_{34}H_{34}NO_7S_2$, m/z 632.1777 [M+H], found 632.1764.

(3*S*,3*aS*,8*S*,8*aR*)-ethyl 1-benzyl-8-(2,2-bis(phenylsulfonyl)ethyl)-3,3*a*,8,8*a*-tetrahydro-1*H*-indeno[2,1-*c*]isoxazole-3-carboxylate (**4g**) (new compound)



Indane **4g** was prepared according to the general procedure from (*E*)-ethyl 3-(2-(formylmethyl)phenyl)acrylate **1a** (35.4 mg, 0.15 mmol, 1.5 equiv.) and *N*-benzylhydroxylamine **3g** (18.5 mg, 0.15 mmol, 1.5 equiv.) to provide the title compound as a white solid (57.7 mg, 91% yield) after flash column chromatography on silica gel.

1H NMR (400 MHz, $CDCl_3$): δ 7.89 (4H, dd, $J = 19.0, 7.9$ Hz), 7.67 (2H, t, $J = 7.4$ Hz), 7.52-7.46 (4H, m), 7.35-7.30 (8H, m), 7.14-7.12 (1H, m), 5.27-5.25 (1H, m), 4.42-4.25 (4H, m), 4.17 (1H, d, $J = 13.7$ Hz), 4.02-3.99 (1H, m), 3.95 (1H, d, $J = 13.8$ Hz), 3.60-3.57 (1H, m), 2.78-2.71 (1H, m), 2.39-2.32 (1H, m), 1.34 (3H, t, $J = 7.1$ Hz).

^{13}C NMR (100 MHz, $CDCl_3$): 171.9, 142.5, 141.4, 138.7, 137.1, 134.9, 134.5, 130.4, 129.4, 129.3, 129.2, 129.2, 128.7, 128.6, 128.4, 127.7, 125.1, 124.2, 83.6, 79.9, 79.4, 77.4, 62.2, 61.9, 56.3, 46.4, 29.7, 14.4.


HPLC: Chiralpak OD-H (hexane/*i*-PrOH, 70/30, flow rate 1 mL/min, $\lambda = 220$ nm),

t_R (minor) = 14.9 min, t_R (major) = 19.1 min; 98% ee.

$[\alpha]_D^{22} = -30.8$ ($c = 1.5$, CHCl_3).

HRMS (ESI) calcd for $\text{C}_{34}\text{H}_{34}\text{NO}_7\text{S}_2$, m/z 632.1777 $[\text{M}+\text{H}]$, found 632.1783.

(3*S*,3*aS*,8*S*,8*aR*)-methyl 8-(2,2-bis(phenylsulfonyl)ethyl)-1-phenyl-3,3*a*,8,8*a*-tetrahydro-1*H*-indeno[2,1-*c*]isoxazole-3-carboxylate (**4h**) (new compound)



Indane **4h** was prepared according to the general procedure from (*E*)-methyl 3-(2-(formylmethyl)phenyl)acrylate **1d** (30.6 mg, 0.15 mmol, 1.5 equiv.) and *N*-phenylhydroxyamine **3a** (16.3 mg, 0.15 mmol, 1.5 equiv.) to provide the title compound as a white solid (54.2 mg, 90% yield) after flash column chromatography on silica gel.

^1H NMR (400 MHz, CDCl_3): δ 7.79-7.12 (19H, m), 4.74 (1H, dd, $J = 7.3, 2.6$ Hz), 4.50 (3H, s), 3.71 (3H, s), 3.66-3.63 (1H, m), 2.71-2.64 (1H, m), 2.55-2.48 (1H, m).

^{13}C NMR (100 MHz, CDCl_3): 170.8, 148.9, 143.0, 141.5, 138.3, 137.2, 134.9, 134.6, 130.1, 129.4, 129.3, 129.3, 129.1, 128.7, 128.7, 125.1, 124.6, 124.6, 118.5, 83.3, 80.1, 76.4, 56.0, 52.7, 46.9, 30.0.


HPLC: Chiralpak AD-H (hexane/*i*-PrOH, 50/50, flow rate 1 mL/min, $\lambda = 220$ nm),

t_R (major) = 14.9 min, t_R (minor) = 27.9 min; 98% ee.

$[\alpha]_D^{22} = -21.0$ ($c = 1.3$, CHCl_3).

HRMS (ESI) calcd for $\text{C}_{32}\text{H}_{28}\text{NO}_7\text{S}_2$, m/z 602.1307 $[\text{M}+\text{H}]$, found 602.1301.

(3*S*,3*aS*,8*S*,8*aR*)-ethyl 8-(2,2-bis(phenylsulfonyl)ethyl)-6-methoxy-1-phenyl-3,3*a*,8,8*a*-tetrahydro-1*H*-indeno[2,1-*c*]isoxazole-3-carboxylate (**4i**) (new compound)



Indane **4i** was prepared according to the general procedure from (*E*)-ethyl 3-(2-(formylmethyl)-4-methoxyphenyl)acrylate **1b** (37.2 mg, 0.15 mmol, 1.5 equiv.) and *N*-phenylhydroxyamine **3a** (16.3 mg, 0.15 mmol, 1.5 equiv.) to provide the title compound as a white solid (63.4 mg, 98% yield) after flash column chromatography on silica gel.

^1H NMR (400 MHz, CDCl_3): δ 7.79-7.10 (16H, m), 6.83 (1H, dd, $J = 8.3, 1.8$ Hz), 6.72 (1H, s), 4.80-4.78 (1H, m), 4.51-4.39 (3H, m), 4.16-4.10 (2H, m), 3.80 (3H, s), 3.67-3.64 (1H, m), 2.73-2.66 (1H, m), 2.57-2.51 (1H, m), 1.24 (3H, t, $J = 7.2$ Hz).

^{13}C NMR (100 MHz, CDCl_3): 170.4, 160.4, 149.2, 144.4, 138.3, 137.2, 134.9, 134.5, 133.4, 130.1, 129.3, 129.3, 129.2, 129.0, 125.8, 124.3, 118.2, 114.9, 109.6, 83.6, 80.0, 76.9, 61.8, 55.7, 55.3, 47.0, 29.7, 14.2.


HPLC: Chiralpak AD-H (hexane/*i*-PrOH, 50/50, flow rate 1 mL/min, $\lambda = 220$ nm),

t_R (major) = 11.0 min, t_R (minor) = 22.8 min; 92% ee.

$[\alpha]_D^{22} = -33.4$ ($c = 1.0$, CHCl_3).

HRMS (ESI) calcd for $\text{C}_{34}\text{H}_{34}\text{NO}_8\text{S}_2$, m/z 648.1726 $[\text{M}+\text{H}]$, found 648.1721.

(3*S*,3*aS*,8*S*,8*aR*)-ethyl 8-(2,2-bis(phenylsulfonyl)ethyl)-5,6-dioxomethylenyl-1-phenyl-3,3*a*,8,8*a*-tetrahydro-1*H*-indeno[2,1-*c*]isoxazole-3-carboxylate (**4j**) (new compound)



Indane **4j** was prepared according to the general procedure from (*E*)-ethyl 3-(6-(2-oxoethyl)benzo[*d*][1,3]dioxol-5-yl)acrylate **1c** (39.3 mg, 0.15 mmol, 1.5 equiv.) and *N*-phenylhydroxyamine **3a** (16.3 mg, 0.15 mmol, 1.5 equiv.) to provide the title compound as a white solid (62.5 mg, 97% yield) after flash column chromatography on silica gel.

¹H NMR (400 MHz, CDCl₃): δ 7.79-7.29 (14H, m), 7.13 (1H, d, *J* = 7.0 Hz), 6.76 (1H, s), 6.63 (1H, s), 5.97 (2H, d, *J* = 8.8 Hz),

4.65 (1H, dd, *J* = 7.1, 2.7 Hz), 4.41-4.34 (3H, m), 4.19-4.11 (2H, m), 3.55-3.51 (1H, m), 2.61-2.54 (1H, m), 2.49-2.42 (1H, m), 1.25 (3H, t, *J* = 10.4 Hz).

¹³C NMR (100 MHz, CDCl₃): 170.2, 149.1, 148.4, 138.2, 137.2, 135.8, 134.9, 134.6, 134.2, 130.1, 129.4, 129.3, 129.2, 124.6, 118.5, 105.2, 105.0, 101.7, 83.3, 80.1, 76.8, 61.8, 56.0, 46.9, 30.2, 14.2.


HPLC: Chiralpak AD-H (hexane/*i*-PrOH, 50/50, flow rate 1 mL/min, λ = 220 nm),

*t*_R (major) = 44.7 min, *t*_R (minor) = 51.8 min; 99% ee.

[α]_D²² = -57.2 (*c* = 1.1, CHCl₃).

HRMS (ESI) calcd for C₃₄H₃₂NO₉S₂, *m/z* 662.1519 [M+H], found 662.1515.

methyl 6-(2,2-bis(phenylsulfonyl)ethyl)-hexahydro-1-phenyl-1*H*-cyclopenta[*c*]isoxazole-3-carboxylate (**4k**) (new compound)



Compound **4k** was prepared according to the general procedure from (*E*)-methyl 6-formylhex-2-enoate **1e** (23.4 mg, 0.15 mmol, 1.5 equiv.) and *N*-phenylhydroxyamine **3a** (16.3 mg, 0.15 mmol, 1.5 equiv.) to provide the title compound as a white solid (52.2 mg, 94% yield) after flash column chromatography on silica gel.

¹H NMR (400 MHz, CDCl₃): δ 7.76 (4H, dd, *J* = 13.4, 7.8 Hz), 7.63-7.58 (2H, m), 7.46 (2H, t, *J* = 7.8 Hz), 7.40 (2H, t, *J* = 7.8 Hz), 7.30-7.26 (2H, m), 7.16 (2H, d, *J* = 8 Hz), 7.00 (1H, t, *J* = 7.3 Hz), 4.90-

4.88 (1H, m), 4.27 (1H, d, *J* = 4.6 Hz), 4.00-3.97 (1H, m), 3.57, (3H, s), 3.46-3.38 (1H, m), 2.40 (3H, s), 2.10-1.97 (2H, m), 1.76-1.68 (1H, m), 1.42-1.37 (1H, m).

¹³C NMR (100 MHz, CDCl₃): 171.0, 149.6, 138.4, 137.4, 134.7, 134.5, 129.9, 129.3, 129.2, 129.2, 129.0, 123.1, 116.4, 84.0, 80.7, 75.6, 52.4, 49.9, 42.2, 30.9, 29.5, 28.3.

HPLC: Chiralpak AD-H (hexane/*i*-PrOH, 70/30, flow rate 1 mL/min, λ = 220 nm),


*t*_R (minor) = 20.7 min, *t*_R (major) = 23.0 min; 94% ee.

[α]_D²⁰ = -81.5 (*c* = 1.0, CHCl₃).

HRMS (ESI) calcd for C₂₈H₃₀NO₇S₂, *m/z* 556.1464 [M+H], found 556.1459.

Experimental data of Compound A

(*E*)-ethyl 3-(2-((*S*)-1-formyl-3,3-bis(phenylsulfonyl)propyl)phenyl)acrylate (**A**) (new compound)



Michael adduct **A** was prepared according to the general procedure from (*E*)-ethyl 3-(2-(formylmethyl)phenyl)acrylate **1a** (35.4 mg, 0.15 mmol, 1.5 equiv.), without the addition of hydroxyamines, to provide the title compound as a white solid (63.4 mg, 87% yield) after flash column chromatography on silica gel.

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 9.55 (1H, s), 8.12 (1H, d, $J = 15.6$ Hz), 7.96-7.94 (2H, m), 7.80-7.79 (2H, m), 7.73-7.64 (3H, m), 7.58 (2H, t, $J = 7.6$ Hz), 7.50 (2H, t, $J = 7.6$ Hz), 7.36 (1H, t, $J = 7.2$ Hz), 7.31-7.29 (1H, m), 6.85-6.84 (1H, m), 6.41 (1H, d, $J = 15.6$ Hz), 4.80-4.76 (1H, m), 4.46-4.43 (1H, m), 4.31-4.26 (2H, m), 2.94-2.86 (1H, m), 2.56-2.48 (1H, m), 1.33 (3H, t, $J = 7.2$ Hz).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): 198.0, 166.3, 140.7, 138.0, 137.3, 135.6, 135.0, 134.9, 133.8, 131.1, 130.2, 129.9, 129.8, 129.4, 129.4, 129.2, 128.3, 123.0, 80.2, 61.1, 52.3, 26.5, 14.5.

HPLC: Chiralpak AD-H (hexane/*i*-PrOH, 70/30, flow rate 1 mL/min, $\lambda = 220$ nm),


t_R (major) = 31.237 min, t_R (minor) = 37.617 min; 97% ee.

$[\alpha]_D^{22} = -51.9$ ($c = 1.4$, CHCl_3).

HRMS (ESI) calcd for $\text{C}_{27}\text{H}_{27}\text{O}_7\text{S}_2$, m/z 527.1198 [M+H], found 527.1211.

Experimental procedure and data for the synthesis α -hydroxy- γ -amino acid derivative **5**:

(*S*)-ethyl 2-((1*S*,2*R*,3*S*)-3-(2,2-bis(phenylsulfonyl)ethyl)-2-(phenylamino)-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxyacetate (**5**) (new compound)



10% Pd/C (30 mg) was added to a solution of indane **4a** (0.1 mmol) in methanol (5.0 mL) at room temperature under an atmosphere of hydrogen by means of a balloon. After stirring overnight, the mixture was filtered through Celite. Removal of the solvent from the filtrate under reduced pressure afforded the α -hydroxy- γ -amino acid derivative **5** as a white solid (60.5 mg, 98% yield).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.91 (2H, d, $J = 7.6$ Hz), 7.68 (1H, t, $J = 7.4$ Hz), 7.55-7.49 (3H, m), 7.38 (2H, d, $J = 7.6$ Hz), 7.30-7.22 (7H, m), 7.04-7.03 (1H, m), 6.82 (1H, t, $J = 7.2$ Hz), 6.64 (2H, d, $J = 7.8$ Hz), 5.39 (1H, d, $J = 9.1$ Hz), 4.41 (1H, d, $J = 9.5$ Hz), 4.35 (1H, s), 4.19-4.10 (1H, m), 4.05 (1H, d, $J = 7.8$ Hz), 3.83-3.73 (2H, m), 3.19-3.11 (1H, m), 3.02 (1H, s), 2.77-2.72 (1H, m), 2.57-2.50 (1H, m), 0.98 (3H, t, $J = 7.1$ Hz).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): 174.0, 146.1, 143.7, 140.9, 138.0, 137.2, 134.8, 134.1, 129.9, 129.7, 129.3, 129.1, 129.1, 128.4, 128.0, 124.9, 123.3, 118.3, 112.9, 79.1, 73.7, 62.3, 62.1, 49.2, 47.1, 30.0, 13.9.

HPLC: Chiralpak IA (hexane/*i*-PrOH, 90/10, flow rate 1 mL/min, $\lambda = 220$ nm),


t_R (minor) = 74.4 min, t_R (major) = 96.0 min; 97% ee.

$[\alpha]_D^{21} = -42.0$ ($c = 1.6$, CHCl_3).

HRMS (ESI) calcd for $\text{C}_{33}\text{H}_{34}\text{NO}_7\text{S}_2$, m/z 620.1777 $[\text{M}+\text{H}]$, found 620.1768.

Experimental procedure and data for the synthesis α -hydroxy- γ -lactam derivative **6**:

(3*S*,3*aS*,8*S*,8*aR*)-8-ethyl-3-hydroxy-5,6-dioxomethylenyl-1-phenyl-3,3*a*,8,8*a*-tetrahydroindeno[2,1-*b*]pyrrol-2(1*H*)-one (**6**) (new compound)



To magnesium turnings (77.8 mg, 32 equiv.), activated by TMSCL (1 drop) and 1,2-dibromoethane (1 drop), was added dropwise a solution of indane **4j** (66.0 mg, 0.1 mmol) in anhydrous methanol (10 mL) with stirring. The mixture was heated to 50 °C to initiate hydrogen generation and then to reflux for 2 hours. After cooling down to room temperature, 2N HCl solution (10 mL) was then added and extracted with ether. The organic extracts were dried over anhydrous sodium

sulfate, filtered, and evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (hexane:ethyl acetate = 7:3) to afford the α -hydroxy- γ -lactam derivative **6** as a pale yellow solid (15.9 mg, 47% yield).

^1H NMR (400 MHz, CDCl_3): δ 7.41-7.24 (5H, m), 7.10 (1H, s), 6.51 (1H, s), 5.93 (1H, s), 4.74 (1H, d, $J = 8.6$ Hz), 4.63 (1H, d, $J = 5.3$ Hz), 4.17 (1H, t, $J = 6.9$ Hz), 3.13 (1H, s), 2.95 (1H, t, $J = 6.6$ Hz), 1.60-1.51 (2H, m), 0.92 (3H, t, $J = 7.3$ Hz).


^{13}C NMR (100 MHz, CDCl_3): 172.7, 148.0, 147.3, 138.5, 137.1, 130.6, 129.3, 126.3, 123.4, 109.0, 105.2, 101.4, 72.0, 65.7, 49.6, 45.6, 27.9, 11.5.

HPLC: Chiralpak AD-H (hexane/*i*-PrOH, 60/40, flow rate 1 mL/min, $\lambda = 220$ nm),

t_R (minor) = 10.0 min, t_R (major) = 13.1 min; 94% ee.



$[\alpha]_D^{21} = -107.7$ ($c = 1.0$, CHCl_3).



HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{20}\text{NO}_4$, m/z 338.1892 $[\text{M}+\text{H}]$, found 338.1389.







Scheme Proposed catalytic cycle and reaction pathway of the sequential reaction.



^1H and ^{13}C NMR Spectra of Compounds 7a-9d and 1a-1e

























































^1H and ^{13}C NMR Spectra of Compounds 4a-4k









































^1H and ^{13}C NMR Spectra of Compound A




^1H and ^{13}C NMR Spectra of Compounds 5



^1H and ^{13}C NMR Spectra of Compound 6




HPLC Spectra of Compounds 4a-4k




Peak Table
 PDA Ch1 220nm 4nm

Peak#	Ret. Time	Area %
1	13.017	99.015
2	39.826	0.985
Total		100.000




Peak Table
 PDA Ch1 220nm 4nm

Peak#	Ret. Time	Area %
1	12.996	50.265
2	40.108	49.735
Total		100.000




Peak Table
 PDA Ch1 220nm 4nm

Peak#	Ret. Time	Area %
1	81.287	1.985
2	114.014	98.015
Total		100.000




Peak Table
 PDA Ch1 220nm 4nm

Peak#	Ret. Time	Area %
1	84.432	56.026
2	116.495	43.974
Total		100.000




Peak Table
 PDA Ch1 220nm 4nm

Peak#	Ret. Time	Area %
1	40.387	99.080
2	47.248	0.920
Total		100.000




Peak Table
 PDA Ch1 220nm 4nm


Peak#	Ret. Time	Area %
1	40.905	50.968
2	47.662	49.032
Total		100.000



Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	29.552	1.094
2	39.528	98.906
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	29.993	57.723
2	40.216	42.277
Total		100.000




Peak Table
 PDA Ch1 220nm 4nm

Peak#	Ret. Time	Area %
1	8.582	97.737
2	46.939	2.263
Total		100.000




Peak Table
 PDA Ch1 220nm 4nm


Peak#	Ret. Time	Area %
1	8.608	50.013
2	47.817	49.987
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	41.924	0.801
2	64.865	99.199
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	42.807	50.135
2	63.002	49.865
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	14.921	0.957
2	19.108	99.043
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	14.297	49.237
2	18.421	50.763
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	14.136	98.729
2	27.901	1.271
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	14.044	49.997
2	27.795	50.003
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	10.950	95.865
2	22.841	4.135
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	11.052	50.744
2	23.176	49.256
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	44.687	99.353
2	51.791	0.647
Total		100.000



Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	43.768	55.343
2	51.182	44.657
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	20.716	3.055
2	23.027	96.945
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	19.652	50.696
2	23.044	49.304
Total		100.000

HPLC Spectra of Compound A




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	31.237	98.374
2	37.617	1.626
Total		100.000




Peak Table		
PDA Ch1 220nm 4nm		
Peak#	Ret. Time	Area %
1	30.732	47.019
2	36.310	52.981
Total		100.000

HPLC Spectra of Compound 5



Peak Table
PDA Ch1 220nm 4nm


Peak#	Ret. Time	Area %
1	74.400	1.384
2	95.985	98.616
Total		100.000



Peak Table
PDA Ch1 220nm 4nm


Peak#	Ret. Time	Area %
1	74.736	51.054
2	98.724	48.946
Total		100.000

HPLC Spectra of Compound 6



Peak Table
PDA Ch1 220nm 4nm

Peak#	Ret. Time	Area %
1	9.960	2.848
2	13.062	97.152
Total		100.000



Peak Table
PDA Ch1 220nm 4nm

Peak#	Ret. Time	Area %
1	10.024	51.399
2	13.130	48.601
Total		100.000